C-Further today announced that Great Ormond Street Hospital Charity (GOSH Charity), the UK’s largest dedicated charitable funder of child health research, has joined Cancer Research Horizons and LifeArc as a core partner in the international consortium. Together, the organizations will…
Geneos Therapeutics, a clinical-stage biotherapeutics company pioneering personalized immunotherapies for cancer (PICs), has announced remarkable clinical results from two long-term patients treated with its novel DNA-based therapy. One patient with glioblastoma multiforme (GBM), an aggressive brain cancer, and another with…
Almirall, S.A., a global biopharmaceutical company dedicated to medical dermatology, announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology (EADV 2025) in Paris. The POSITIVE…
Arlington Capital Partners a Washington, D.C.–based private investment firm with a focus on government-regulated industries, announced today that its portfolio company TEAM Technologies (“TEAM Tech”) has acquired TAG3 Engineering, LLC (“TAG3”). TEAM Tech is a leading provider of end-to-end outsourced…
Ollin Biosciences Launches with $100 Million Financing to Advance Next-Generation Ophthalmology Therapies Ollin Biosciences, Inc., a newly established clinical-stage biopharmaceutical company, announced its launch with an initial $100 million financing round led by ARCH Venture Partners, Mubadala Capital, and Monograph…
Prota Therapeutics Pty Ltd., a clinical-stage biotechnology company developing novel oral immunotherapy (OIT) treatments for food allergies, today announced that clinical research conducted in partnership with the Murdoch Children’s Research Institute (MCRI) was awarded a prestigious prize at the 2025…
Tasca Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of CP-383 for Advanced Solid Tumors Tasca Therapeutics, a clinical-stage biotechnology company dedicated to developing targeted therapies for genetically defined cancers, announced today that the first patient has been dosed…
Apollo Therapeutics Reports Positive Phase 2a Results for Camoteskimab in Atopic Dermatitis Apollo Therapeutics, a leading portfolio biopharmaceutical company, announced today positive topline results from its Phase 2a CHAMELEON trial evaluating camoteskimab, an investigational anti-IL-18 monoclonal antibody, in patients with…
Echo Receives 2025 Global Recognition Award for Innovation in Hydrogen Water Technology Echo, a leader in wellness and hydration technology, has been honored with a 2025 Global Recognition Award™, a distinction that acknowledges the company’s pioneering role in hydrogen water…
Covalon Announces Publication of Clinical Study Demonstrating Significant Reduction in CLABSIs with VALGuard® Line Guard Covalon Technologies Ltd., an advanced medical technologies company, today announced the publication of peer-reviewed clinical results demonstrating the effectiveness of Covalon’s VALGuard® Vascular Access Line…
Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma Areteia Therapeutics, Inc. announced today that its Phase III EXHALE-4 clinical trial has met key efficacy and safety endpoints for dexpramipexole, an investigational oral therapy being developed as…
Impulse Space, a U.S.-based leader in in-space transportation, and Infinite Orbits, a France-based company specializing in in-orbit services, have expanded their collaboration by signing a new multi-launch agreement. The deal will deliver multiple Infinite Orbits spacecraft to geostationary orbit (GEO)…